insulin glargine Archives

Lannett provides update on biosimilar insulin aspart and insulin glargine products

by Bioblast Editor | Jan 4, 2023 | Biosimilars updates

Lannett provided an update on its biosimilar insulin aspart and insulin glargine products. Lannett reported that its study of its biosimilar insulin aspart product indicated that the product was highly comparable with NovoLog®. Lannett announced that it plans to file...

FDA approves Rezvoglar® (biosimilar insulin glargine) as interchangeable

by Bioblast Editor | Nov 18, 2022 | Biosimilars updates

The FDA approved Eli Lilly’s Rezvoglar® (biosimilar insulin glargine) as an interchangeable biosimilar to Lantus®. Rezvoglar was approved as a biosimilar in December 2021.

Viatris voluntarily recalls one US batch of biosimilar insulin glargine due to missing labels

by Bioblast Editor | Jul 5, 2022 | Biosimilars updates

Viatris announced that it was voluntarily recalling one batch of insulin glargine 100 units/mL, 3mL prefilled pens (batch BF21002895) due to the potential for the label to be missing on some pens. This recall pertains only to the unbranded interchangeable biosimilar...

Civica selects Profil as clinical trial partner for affordable insulin initiative

by Bioblast Editor | Jun 2, 2022 | Biosimilars Deals 2022, Biosimilars updates

Civica announced that is has selected Profil as its clinical trial partner to support the development of its affordable insulin initiative. In March 2020, Civica announced its plan to manufacture biosimilar insulins glargine, lispro and aspart. Civica plans to set a...

Lannett provides update on biosimilar insulin glargine trials

by Bioblast Editor | Jun 1, 2022 | Biosimilars updates

Lannett provided an update on its pivotal clinical trials of biosimilar insulin glargine. Lannett announced that half of the subjects have received the first two doses in healthy volunteer pharmacokinetics (PK) and pharmacodynamics (PD) study. No serious adverse...